Clinico-epidemiological Profile, Comorbidities, Prevailing Practices in the Management of Hyperuricemia and Patient Outcomes with Various Urate Lowering Therapies: Capital Registry Data
Hyperuricemia Registry Study
Article Sidebar
Main Article Content
Abstract
Background: The absence of standardized protocols for managing hyperuricemia (HU) in chronic kidney disease (CKD) patients in India highlights the need to examine current practices. This registry assessed clinico-epidemiological data, treatment strategies, and outcomes with urate-lowering drugs (ULD) in CKD stages 2 to 4 across India.
Methods: This observational registry included 251 CKD patients with HU across five centers over 12 months. Primary endpoints were demographic data, CKD stages, and comorbidities. Secondary endpoints included percentages of patients on treatment (ULD, lifestyle modification [LSM], or both) and their impact on kidney function tests (KFTs). Comparisons were made between therapies (LSM vs. LSM+ULD) and comorbidity subgroups.
Results: Among 251 CKD patients, 48.6% had stage 4 CKD, and 58.2% had SUA levels 6-8 mg/dL (mean age: 46.77 years; 69.7% men). Hypertension (90%) was most common, followed by diabetes (41%).
At 12 months, mean SUA reduction was significant (-2.36 ± 1.85). Similar reductions occurred in patients with comorbidities: diabetes (-2.52 ± 1.83), hypertension (-2.39 ± 1.86), diabetes + hypertension (-2.51 ± 1.84) and others (-2.83 ± 2.06). Reduction was greater in patients treated with LSM+ULD (-2.89 ± 1.64) compared to LSM alone (-0.62 ± 1.69).
A significant eGFR increase was noted overall, with ULD+LSM group showing higher eGFR (15.21 ± 25.61) than LSM-only group (-1.26 ± 10.41). Seventeen adverse events (AEs) and three serious AEs were reported, all except one were unrelated.
Conclusion: The study highlights younger onset, male predominance, and higher ULD use in Indian CKD patients with hyperuricemia, supporting potential benefit of ULD+LSM in the management of CKD.
Article Details
Copyright (c) 2026 Jasuja S, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Sanjiv Jasuja, Indraprastha Apollo Hospital, New Delhi, India
MD-Nephrologist
Sanjeev Hiremath, Sanjeev Clinic, 22nd Cross Road, Banashankari, StageII, Bengaluru, Karnataka, 560070 India
DM-Nephrologist
Shankar Prasad Nagaraju, Department of Nephrology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India
DM-Nephrologist
Manish Balwani, Saraswati Kidney Care Center (A unit of SS Multispeciality Hospital), Nagpur, 440015 Maharashtra, India
MD-Nephrologist
Amit Pasari, Saraswati Kidney Care Center (A unit of SS Multispeciality Hospital), Nagpur, 440015 Maharashtra, India
MD (Medicine), DM (Nephrology), SCE (Nephrology), FCRP (London), FASN, FISN, Nephrologist
Pai BH, Swarnalatha G, Ram R, Siva Kumar V. Allopurinol for prevention of progression of kidney disease with hyperuricemia. Indian J Nephrol. 2013;23(4):280-6. Available from: https://doi.org/10.4103/0971-4065.114499
Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med. 2002;69(8):594, 597, 600-2. Available from: https://doi.org/10.3949/ccjm.69.8.594
Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654-61. Available from: https://doi.org/10.1038/nrrheum.2014.124
Zhang X, Liu L, Liang R, Jin S. Hyperuricemia is a biomarker of early mortality in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:2519-23. Available from: https://doi.org/10.2147/copd.s87202
Kleber ME, Delgado G, Grammer TB, Silbernagel G, Huang J, Krämer BK, et al. Uric acid and cardiovascular events: a Mendelian randomization study. J Am Soc Nephrol. 2015;26(11):2831-8. Available from: https://doi.org/10.1681/asn.2014070660
Freilich M, Arredondo A, Zonnoor SL, McFarlane IM. Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions. Cureus. 2022;14(3):e23625. Available from: https://doi.org/10.7759/cureus.23582
George C, Leslie SW, Minter DA. Hyperuricemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Aug 6]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499945/
Global prevalence of hyperuricemia: a systematic review of population-based epidemiological studies [Internet]. American College of Rheumatology; 2015 [cited 2024 Aug 6]. Available from: https://acrabstracts.org/abstract/global-prevalence-ofhyperuricemia-a-systematic-review-of-population-based-epidemiological-studies/
Billa G, Dargad R, Mehta A. Prevalence of hyperuricemia in Indian subjects attending hyperuricemia screening programs-a retrospective study. J Assoc Physicians India. 2018;66(4):43-6.
Levin A, Baumgartner L, Coresh JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684-701. Available from: https://doi.org/10.1016/j.kint.2023.10.016
Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52(1):283-9. Available from: https://doi.org/10.1002/art.20761
Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51-9. Available from: https://doi.org/10.1053/j.ajkd.2005.10.006
Gout treatment guidelines [Internet]. Arthritis Foundation; [cited 2024 Aug 6]. Available from: https://www.arthritis.org/diseases/more-about/gout-treatment-guidelines
Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017;56(7):1056-9. Available from: https://doi.org/10.1093/rheumatology/kex156
Hisatome I, Ogino K, Kotake F. Japanese Society of Gout and Uric & Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd edition. Gout Uric Nucleic Acids. 2020;44:1-37.
Sato Y, Feig DI, Stack AG, Kang DH, Lanaspa MA, Ejaz AA, et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019;15(12):767-75. Available from: https://doi.org/10.1038/s41581-019-0174-z
Bonino B, Murea M, Linville L. Uric acid in CKD: has the jury come to the verdict? J Nephrol. 2020;33(4):715-24. Availablefrom: https://doi.org/10.1007/s40620-020-00702-7
Kamatani N, Fujimori S, Hieda S. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S44-9.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease [Internet]. 2013 [cited 2024 Aug6]. Available from:https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
Sonoda H, Takase O, Kato N, Kimura G. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol. 2011;33(4):352-7. Available from: https://doi.org/10.1159/000326848
Yamada T, Fukatsu M, Suzuki S, Wada T, Joh T. Elevated serum uric acid predicts chronic kidney disease. Am J Med Sci. 2011;342(6):461-6. Available from: https://doi.org/10.1097/maj.0b013e318218bd89
Mwasongwe SE, Fülöp T, Katz R, Musani SK, Sims M, Correa A, et al. Relation of uric acid level to rapid kidney function decline and development of kidney disease: The Jackson Heart Study. J Clin Hypertens (Greenwich). 2018;20(4):775-83. Availablefrom: https://doi.org/10.1111/jch.13239
Son YB, Yang JH, Kim MG, Jo SK, Cho WY, Oh SW. The effect of baseline serum uric acid on chronic kidney disease in normotensive, normoglycemic, and non-obese individuals: a health checkup cohort study. PLoS One. 2021;16(1):e0244106. https://doi.org/10.1371/journal.pone.0244106
Toyama T, Furuichi K, Shimizu M, Hara A, Iwata Y, Sakai N, et al. Relationship between serum uric acid levels and chronic kidney disease in a Japanese cohort with normal or mildly reduced kidney function. PLoS One. 2015;10(9):e0137449. Availablefrom: https://doi.org/10.1371/journal.pone.0137449
Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642-50.
Johnson RJ, Lozada LGS, Lanaspa MA, Piani F, Borghi C. Uric acid and chronic kidney disease: still more to do. Kidney Int Rep. 2023;8(2):229-39. Available from: https://doi.org/10.1016/j.ekir.2022.11.016
Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19(6):1204-11. Available from: https://doi.org/10.1681/asn.2007101075
Prezelin-Reydit M, Speyer R, Saad N. Longitudinal uric acid has nonlinear association with kidney failure and mortality in chronic kidney disease. Sci Rep. 2023;13(1):17602.
Yin Y, Zhou E, Wu J. Association between hyperuricemia and long-term mortality in patients with hypertension: results from the NHANES 2001-2018. Front Cardiovasc Med. 2024;11:1347917.
Weis L, Metzger M, Haymann JP, Thervet E, Flamant M, Vrtovsnik F, et al. Renal function can improve at any stage of chronic kidney disease. PLoS One. 2013;8(12):e81835. Availablefrom: https://doi.org/10.1371/journal.pone.0081835
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-35. Available from: https://doi.org/10.1053/j.ajkd.2014.01.416
Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388-93. Available from: https://doi.org/10.2215/cjn.01580210
Zhang TJ, Zhang X, Xu EY, Wang ZR, Zhang ZH, Wang QY, Wang L, Wen YQ, Meng FH. A possible covalent xanthine oxidase inhibitor TS10: Inhibition mechanism, metabolites identification and PDPK assessment. Bioorg Chem. 2022 Nov;128:106064. Available from: https://doi.org/10.1016/j.bioorg.2022.106064
Maruyama Y, Tanaka T, Tanabe K, et al. Effect of uric acid-lowering therapy on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Replace Ther. 2021;7(1):15.